Lantern Pharma Launches ZetaOmics with Early Access to 615,000 Cancer Samples
LTRN•Lantern Pharma launched ZetaOmics, its autonomous computational-biology module within the withZeta.ai platform, offering expert-grade multi-omic analysis using over 615,000 curated cancer samples. The tool enters an early-access program with leading bioinformatics teams to refine workflows before commercial rollout.
1. Launch Details
Lantern Pharma introduced ZetaOmics as the computational-biology module of its withZeta.ai multi-agent AI co-scientist platform. This autonomous agent performs end-to-end bioinformatics and multi-omic analysis across any cancer type, encoding expert judgment to prevent false discoveries and ensure statistical rigor.
2. Key Features
ZetaOmics leverages direct access to more than 615,000 curated cancer samples across eleven data sources, autonomously resolving fragmented data and building meaningful cohorts from natural-language queries. It delivers publication-quality outputs—differential expression, pathway enrichment, survival modeling, and drug-response analysis—in minutes within a single conversational workflow.
3. Early-Access Program
The module enters an early-access phase with select academic and industry bioinformatics teams and Lantern collaborators. This phased rollout will validate performance against demanding research workflows and guide refinement ahead of broader commercial availability.
4. Commercial Outlook
Lantern Pharma aims to seed subscription and partnership revenue by embedding ZetaOmics in regulated research environments, targeting both common and rare cancers. The company expects this non-dilutive growth engine to drive durable revenue while accelerating its own oncology pipeline development.
